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ABSTRACT
Daratumumab (DARA) is an FDA-approved high-affinity monoclonal antibody
targeting CD38 that has shown promising therapeutic efficacy in double refractory
multiple myeloma (MM) patients. Despite the well-established clinical efficacy of DARA,
not all heavily pretreated patients respond to single-agent DARA, and the majority of
patients who initially respond eventually progress. Antibody-drug conjugates (ADCs)
combine the highly targeted tumor antigen recognition of antibodies with the cell
killing properties of chemotherapy for effective internalization and processing of the
drug. In this study, we evaluated the anti-tumor efficacy of DARA conjugated to the
maytansine derivative, mertansine (DM1), linked via a non-cleavable bifunctional
linker. The ADC was labelled with the near-infrared (NIR) fluorophore IRDye800
(DARA-DM1-IR) to evaluate its stability, biodistribution and pharmacokinetics in
vitro and in vivo. We demonstrated the conjugation of: 1) DM1 enhanced tumorkilling efficacy of the native DARA and 2) IRDye800 allowed for visualization of
uptake and tumor targeting ability of the ADC. With the advent of other classes of
immunoconjugates for use in MM, we reasoned that such imaging techniques can be
utilized to evaluate other promising conjugates in preclinical MM models on a wholebody and cellular level.

INTRODUCTION

therapeutic index is to introduce additional drugs to
complement the multiple mechanisms of action of the
native immunotherapy. Antibody-drug conjugates (ADCs)
combine the highly targeted tumor antigen recognition of
antibodies with the cell killing properties of chemotherapy
for effective internalization and processing of the drug.
The ADC is designed to provide a wider therapeutic
window than the antibody alone or the parent cytotoxic
drug payload attached to it. Drugs such as maytansines
are potent tubulin inhibitors that have previously failed
FDA approval due to their poor therapeutic window and
lack of tumor specificity, but have demonstrated excellent
stability and acceptable solubility in aqueous solutions
for use in other clinically-approved ADCs [4]. In this
study, we evaluated the anti-tumor efficacy of DARA
conjugated to the maytansine derivative, mertansine

Daratumumab (DARA) is a human IgG1
monoclonal antibody that targets Cluster of Differentiation
38 (CD38), inducing tumor cell death through multiple
mechanisms, including antibody-dependent cellmediated cytotoxicity (ADCC), complement-dependent
cytotoxicity, and antibody-dependent cellular phagocytosis
(ADCP) [1]. Despite the well-established clinical efficacy
of DARA in relapsed and refractory multiple myeloma
(MM) patients, not all of the heavily pretreated patients
respond to single-agent DARA therapy, and the majority
of patients who initially respond eventually progress [2].
This may be due to upregulation of pathways that inhibit
DARA-mediated ADCC and CDC [3]. One possibility
for enhancing the potency of DARA and increasing its
www.oncotarget.com
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RESULTS

(DM1), linked via the non-cleavable bifunctional linker
succinimidyl
4-(N-maleimidomethyl)cyclohexane-1carboxylate (SMCC) (DARA-DM1). The SMCC linker
contains a thioether bond, requiring complete lysosomal
degradation of the ADC for intracellular release of the
payload, and has demonstrated improved in vivo stability
and reduced off-target toxicity compared to ADCs with
cleavable linkers [5]. The cleaved drug product, lysineSMCC-DM1, contains a net positive charge, allowing
for improved retention in the target cell following
internalization of the ADC [6]. We posit that DARA
conjugated to DM1 via a non-cleavable linker will enhance
the potency of the native DARA while maintaining high
MM tumor specificity and in vivo stability.
Binding and internalization of an ADC play
critical roles in a biologic’s overall therapeutic potential
and delivery of the cytotoxic drug to the target tumor
cell. Molecular imaging can serve as a powerful
tool to evaluate uptake of antibody-based therapies
and provide significant insights into designing nextgeneration therapeutic agents with superior safety
and efficacy. Traditionally, such imaging studies are
performed through imaging of radiolabeled compounds
with Positron Emission Tomography (PET) or SinglePhoton Emission Computed Tomography (SPECT).
While PET and SPECT are highly sensitive and can
be used to measure tracer uptake into tissues, the use
of decaying radioisotopes and ability to trace just one
molecular species (in the case of PET) in a given imaging
experiment does not allow for longitudinal monitoring
of interactions between molecular targets [7]. Labelling
with fluorescent probes for optical imaging in the first
near-infrared (NIR-I) window (650–950 nm) allows
for reduced autofluorescence in vivo than in the visible
fluorescence range (400–650 nm) on a whole-body
and cellular level in preclinical animal models [8].
While there have been preclinical efforts in developing
fluorescently-labelled ADCs for solid cancers [9,
10], there have been no published studies evaluating
fluorescently-labelled ADCs in preclinical models of MM
or other hematologic malignancies.
Here, we labelled DARA-DM1 with the NIR
fluorophore IRDye800 (Ex./Em. 774 nm/810 nm)
(DARA-DM1-IR). In addition to efficacy, we evaluated
specificity of the ADC, in relation to the native antibody,
to myeloma tumor cells both in vitro and in vivo. We
hypothesize that: 1) the conjugation of the drug will
enhance the therapeutic efficacy of DARA without
affecting tumor targeting of the DARA antibody and
2) labelling with the NIR fluorophore will allow for
visualization of DARA-DM1 on a whole-body and
cellular level. The proof of principle studies in this article
demonstrated the potential of NIR fluorescence imaging
for evaluating the cellular uptake and biodistribution of
antibody-based therapies in preclinical MM and other
hematologic cancers.
www.oncotarget.com

Synthesis and characterization of DARA-DM1
and DARA-DM1-IR
DM1 was conjugated to DARA at a molar ratio of 20
to 1. Mass spectrometry was performed on DARA-DM1
to calculate a drug to antibody ratio (DAR) of 3.2 with less
than 10% of unconjugated DARA remaining following
DM1 conjugation (Supplementary Figure 1A). Following
DM1 conjugation, IRDye800 was labelled to DARA-DM1
and DARA at a dye to antibody ratio of 3 to 1. Absorption
spectroscopy showed a similar degree of labelling (DOL)
of IRDye800 to both DARA-DM1 and DARA at ~1.3–1.4
(Supplementary Figure 1B). Fluorescence spectroscopy
confirmed that there was not a difference in brightness
between the two conjugates (Supplementary Figure 1C).

Cytotoxicity of DARA-DM1 and DARA-DM1-IR
To evaluate the in vitro cytotoxicity of DARADM1 compared to the native DARA antibody, DARA
conjugates were incubated with two human myeloma cell
lines, MM.1S and U266, in a dose-dependent fashion.
CD38 expression was evaluated on both cell lines via flow
cytometry showing high and low expression of CD38 on
MM.1S and U266 cell lines, respectively (Figure 1A).
DARA-DM1 and DARA-DM1-IR both exhibited a
statistically significant difference in cytotoxicity in MM.1S
cells (DARA-DM1 IC50: 0.43 ± 0.05 µg/mL; DARADM1-IR IC50: 0.40 ± 0.03 µg/mL) compared to U266
cells (DARA-DM1 IC50: 2.54 ± 0.4 µg/mL; DARA-DM1IR IC50: 4.58 ± 0.7 µg/mL) (p < 0.0001). Conjugation
of IRDye800 to DARA-DM1 did not show a statistical
difference in tumor-killing ability when compared to
DARA-DM1 in MM.1S cells, but showed a statistical
difference in U266 cells (p < 0.0001) (Figure 1B).

Evaluation of stability, binding and
internalization properties of IRDye800conjugated antibodies
Stability of DARA-IR and DARA-DM1-IR in
Phosphate Buffer Saline (PBS) and human serum was
measured over 7 days. Both IRDye800 conjugates
maintained >80% NIR signal by day 7, indicating
minimal dye deconjugation and formation of free dye
during incubation (Supplementary Figure 2). Flow
cytometry and fluorescence microscopy were performed
to determine if conjugation of IRDye800 to the ADC
perturbed the antibody’s binding property. DARA-DM1IR demonstrated significant binding in MM.1S and U266
cells in a CD38-dependent manner (MM.1S: 86.8 ±
0.9%; U266: 43.6 ± 0.4%). Blocking of CD38 receptor
with excess DARA demonstrated significantly reduced
binding of DARA-DM1-IR in both cell lines (MM.1S:
2040
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6.46 ± 1.1%; U266: 1.53 ± 0.5%) (Figure 1C). Evaluation
by flow cytometry of the lysosomal-associated membrane
protein 1 (LAMP-1) staining in MM.1S and U266
cells corresponded with binding, showing significant
intracellular internalization of both DARA conjugates in
MM.1S cells (DARA-IR: 96.2 ± 0.3%; DARA-DM1-IR:
98.5 ± 0.1%), but significantly reduced internalization in
U266 cells (DARA-IR: 12.7 ± 0.7%; DARA-DM1-IR:
12.2 ± 1.8%) (Supplementary Figure 3). Fluorescence
microscopy of MM.1S cells incubated with both DARA
conjugates confirmed flow cytometric LAMP-1 staining
results, showing significant internalization within 3 hours
(Figure 1D).

imaging (BLI). DARA-DM1 resulted in significant tumor
eradication following single administration and showed
sustained reduction in tumor burden at all BLI time points
when compared to untreated mice. Unconjugated DARA,
conversely, began demonstrating a significant reduction in
tumor burden only at 33 days following tumor inoculation
(Figure 2A). A significant difference in tumor burden was
also observed in mice treated with DARA-DM1 compared
to DARA at Day 14 (p < 0.0001). No significant weight
loss was demonstrated in any of the untreated or treated
(DARA and DARA-DM1) mice (Supplementary Figure 4).
Ex vivo flow cytometry on excised femoral and pelvic
bone marrow, gated for live, GFP+ tumor cells, verified the
anti-MM effect seen with in vivo BLI results (Figure 2B).

In vivo therapeutic efficacy of DARA-DM1

High specificity of DARA-DM1-IR conjugate to
CD38+ myeloma extramedullary tumors

To demonstrate the therapeutic efficacy of DARADM1 in vivo, fox chase severe combined immunodeficient
(SCID) beige mice injected intravenously (IV) with
MM.1S cells transfected with green fluorescence protein
(GFP) and luciferase (MM.1S IV) were treated with
either DARA or DARA-DM1 at doses of 4 mg/kg of
body weight and were monitored with bioluminescence

To quantify contrast and the optimal imaging time
point of DARA-DM1-IR, SCID beige mice bearing
subcutaneous (SQ) tumor xenografts (MM.1S SQ) were
injected IV with the fluorescent conjugate. Significant
uptake of DARA-DM1-IR was observed in GFP+ tumor-

Figure 1: In vitro evaluation of cytotoxicity, binding and internalization of DARA-DM1-IR. (A) Flow cytometric evaluation

of CD38 expression in human MM.1S and U266 myeloma cells. (B) Comparison of cytotoxicity of DARA-DM1 and DARA-DM1-IR and
control DARA and DARA-IR in human MM.1S and U266 myeloma cells. All experiments were performed in triplicate and repeated twice.
Two-way ANOVA followed by Sidak’s multiple comparison’s test was performed on IC50 values. (C) Percentage cell binding of DARADM1-IR in MM.1S and U266 cells at 37°C in the absence and presence of 50-fold blocking dose of unlabelled DARA. Two-way ANOVA
followed by Sidak’s multiple comparison’s test was performed. (D) Live cell fluorescence microscopy of internalization of DARA-IR
and DARA-DM1-IR in MM.1S-GFP-luc cells 3 hours post-incubation. Magnification: 20×; Scale bar: 20 µm. ****p < 0.0001. Error bars
represent standard deviation.
www.oncotarget.com
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bearing regions by day 9 of fluorescent imaging (Figure
3A). Region of Interest (ROI) analysis of small-animal
fluorescent imaging with DARA-DM1-IR showed high
contrast, calculated as Tumor to Background Ratio (TBR),
at later time points, reaching a peak of 3.3 ± 0.4 at day 9
as compared to a TBR of 4.0 ± 0.7 in mice injected with
DARA-IR (Figure 3B). This optimal time point informed
the imaging in studies involving the MM.1S IV mouse
model. A statistically significant difference in TBRs
between DARA-DM1-IR and DARA-IR was observed at
Day 8 (p < 0.01) and 9 (p < 0.05). Tissue biodistribution
studies performed in the IRDye800 channels at 2, 7 and 9
days post administration of DARA-DM1-IR and DARAIR were in agreement with the in vivo fluorescent imaging
data, calculated as Tissue to Muscle Ratio (TMR),

showing high uptake and retention of the fluorescent
conjugate 9 days after injection (DARA-DM1-IR TMR:
13.9 ± 2.6; DARA-IR TMR: 15.5 ± 4.8) (Figure 3C).
Significant differences in non-tumor tissue were observed
primarily in the liver with greater uptake of DARADM1-IR at day 2 (DARA-DM1-IR TMR: 50.6 ± 17.1;
DARA-IR TMR: 22.8 ± 4.2) and day 7 (DARA-DM1-IR
TMR: 19.2 ± 2.6; DARA-IR TMR: 14.2 ± 2.2) (Figure
3C). Similar liver uptake was observed between the two
antibody conjugates by day 9 (DARA-DM1-IR TMR: 12.2
± 0.9; DARA-IR TMR: 11.9 ± 1.6). Immunofluorescence
staining of excised tumors supported in vivo and ex vivo
imaging results and demonstrated specific binding of
DARA-DM1-IR, similarly to DARA-IR, to tumor cells
(Figure 3D).

Figure 2: In vivo therapeutic efficacy of DARA-DM1 in intramedullar myeloma mice. (A) Longitudinal BLI of MM.1S

IV mice treated with a single dose of DARA or DARA-DM1 measured as bioluminescence flux (photons/sec/cm2/sr). n = 6–7/group.
Repeated measures two-way ANOVA followed by Sidak’s multiple comparison’s test was performed. (B) Representative flow cytometry
from excised bone marrow of untreated and treated mice, gating for live, GFP+ MM cells. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Error bars represent standard deviation.
www.oncotarget.com
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High specificity of DARA-DM1-IR conjugate to
CD38+ myeloma intramedullary tumors

both conjugates in bone regions (DARA-DM1-IR TMR:
20.4 ± 7.2; DARA-IR TMR: 18.4 ± 2.2) and greater uptake
than in bones from mice injected with a non-specific IgGIR (IgG-IR TMR: 8.2 ± 1.1). Liver uptake of DARADM1-IR (TMR: 43.3 ± 15.4) was similar to IgG-IR (TMR:
43.8 ± 6.6) and was higher than the uptake of DARA-IR
(TMR: 23.0 ± 7.6) (Figure 5A). Flow cytometry on the
excised bone marrow, measured as mean fluorescence
intensities (MFI), confirmed in vivo and ex vivo images
and showed significantly increased uptake of DARADM1-IR (MFI: 9832 ± 1545) and DARA-IR (MFI: 11715

In vivo fluorescent imaging of DARA-DM1-IR was
also performed in the MM.1S IV mouse model. Similar to
the SQ mouse model, DARA-DM1-IR showed specificity
to GFP+ tumors in marrow-rich regions such as the skull,
long bones and spine (Figure 4A and 4B) 9 days post
administration. Tissue biodistribution studies in tumor and
non-tumor tissue from mice injected with DARA-DM1IR and DARA-IR, respectively, showed similar uptake of

Figure 3: High contrast observed with DARA-DM1-IR at longer time points in MM.1S SQ mice. (A) Representative

IRDye800 in vivo images of MM.1S SQ mice 2 and 9 days post administration of DARA-DM1-IR and DARA-IR. (B) Plot of calculated
Tumor to Background Ratios (TBRs) in MM.1S SQ mice across individual time points following administration of DARA-DM1-IR and
DARA-IR. Background is defined as the non-tumor, contralateral left flank of the mouse. Repeated measures two-way ANOVA followed
by Sidak’s multiple comparison’s test was performed on TBR data. n = 3–4/group. (C) Normalized biodistribution (defined as tissue to
muscle ratio (TMR)) of DARA-DM1-IR 2, 7 and 9 days after administration of fluorescent conjugate. n = 3–4/group. Two-way ANOVA
followed by Sidak’s multiple comparisons test was performed on biodistribution data. (D) Immunohistochemistry of excised tumor sections
from mice injected with DARA-DM1-IR and DARA-IR. Nuclear stain was performed with Hoechst 33342. Magnification: 40×; Scale bar:
100 µm. *p < 0.05; **p < 0.01; ****p < 0.0001. Error bars represent standard deviation.
www.oncotarget.com
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± 3475) relative to IgG-IR (MFI: 319 ± 86.75) with no
significant difference between uptake of DARA-DM1-IR
and DARA-IR (Figure 5B).

such as Blenrep (anti-BCMA) [14], and other ADCs
undergoing clinical trial, such as IMGN901 (anti-CD56)
[15], the potential of ADCs and similar immunoconjugates
will be increasingly evaluated in such heavily pretreated
MM patients. The general mechanism of cytotoxicity for
such immunoconjugates includes binding and subsequent
internalization into the cell, cleavage of the linker-drug
complex and the release of the payload for killing the
target cell [16]. The payloads of the ADCs described
previously either damage DNA or impede microtubule
assembly while retaining all the mechanisms of action of
the native antibody, introducing an additional mechanism
to overcome drug insensitivity [17, 18]. We reasoned that
a similar conjugation of a cytotoxic drug to DARA could
also widen its therapeutic window.
Here we demonstrate the use of DARA conjugated
to the non-cleavable linker SMCC and the maytansinoid
DM1 because of the improved in vivo stability and reduced
bystander killing associated with drug payloads linked
via non-cleavable linkers [4]. Free DM1 has also shown
significant cytotoxicity to MM cells in vitro [19]. DARA has
demonstrated preferential killing of high CD38-expressing
MM cells, allowing for expansion of MM cells with low
CD38 (CD38low) expression with reduced CDC and ADCC
killing [13]. With the immunosuppressive nature of non-

DISCUSSION
CD38 is highly expressed on MM cells and is
involved in their development and proliferation, making
CD38 an attractive therapeutic target. DARA was the
first Food and Drug Administration (FDA)-approved
anti-CD38 immunotherapy prescribed to relapsed and
refractory MM patients. While DARA is well tolerated
and has robust clinical efficacy, not all heavily pretreated
patients respond to single-agent DARA, necessitating
other therapeutic agents to overcome this resistance [3, 11].
Several mechanisms have been proposed that are driving
DARA resistance, including upregulation of complement
inhibitors, clonal selectivity and microenvironmental
interactions with bone marrow stromal cells [12]. CD38
expression is excluded as a possible reason, as responders
and non-responders of DARA treatment show a marked
reduction in CD38 [13]. A highly appealing strategy is
to utilize the targeting power of antibodies as carriers
of potent effector moieties to the target tumor cell. With
the recent success of clinically-approved ADCs in MM,

Figure 4: Specific binding of DARA-DM1-IR to cancerous bone marrow regions in MM.1S IV mice. (A) Representative
images of GFP and IRDye800 fluorescence in vivo of skull, long bones and spine (yellow arrows) in separate MM.1S IV models 9 days
post administration of DARA-DM1-IR. (B) Representative GFP and IRDye800 fluorescent images of excised 1) blood 2) heart 3) lung 4)
liver 5) spleen 6) kidney 7) bone 8) muscle 9) brain from mice. a.u. stands for arbitrary units.
www.oncotarget.com
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responders to DARA therapy [12, 20, 21], we believe the
ADC could potentially target and kill CD38low MM cells
in the presence of reduced effector cell populations that
DARA is reliant upon. We anticipate that DARA-DM1 will
allow for a greater percentage of DM1 drug to reach tumors,
lowering the minimum effective dose and elevating the
maximum tolerated dose of drug payload. To evaluate the
binding, internalization and distribution of DARA-DM1, we
labelled the ADC with the NIR fluorophore IRDye800. With
the advent of anti-CD38 ADCs [22], radiotherapies [23] as
well as other classes of immunotoxins for use in MM [18],
the NIR-labelling techniques applied in this manuscript can
be used to visualize similar immunoconjugates in preclinical
MM models in vitro and in vivo for more efficient clinical
translation in MM.
At a DAR of 3.2, DARA-DM1 was found to
have less than 10% DARA remain unconjugated. As

expected with lysine-based conjugation, a heterogeneous
distribution of 1–5 DM1 molecules was conjugated
to DARA. While IRDye800 also requires free lysines
for conjugation, preferentially on the heavy chain of
the antibody [24, 25], absorbance and fluorescence
spectroscopy demonstrated a similar DOL of ~1.3-1.4
between DARA-DM1-IR and DARA-IR without any
differences in fluorescence emission. This suggests that
the presence of DM1 and the heterogeneity of lysine
conjugation did not inhibit labelling of IRDye800 to the
DARA antibody.
Two human MM cell lines, MM.1S and U266,
with different levels of CD38 expression were utilized
to evaluate the cytotoxicity and mechanism of action of
the DARA immunoconjugates. We demonstrated that
conjugating DM1 enhanced cytotoxicity of the native
DARA in a CD38-dependent fashion. DARA, conversely,

Figure 5: Biodistribution and flow cytometric analysis of DARA-DM1-IR in MM.1S IV mice. (A) Normalized biodistribution
(defined as TMR) of DARA-DM1-IR, DARA-IR and IgG-IR 9 days after administration of fluorescent conjugate. n = 3–4/group. Twoway ANOVA followed by Sidak’s multiple comparisons test was performed on biodistribution data. (B) Flow cytometric analysis of
IRDye800 MFIs from excised bone marrow of DARA-DM1-IR, DARA-IR and IgG-IR-injected mice. One-way ANOVA followed by
Tukey’s multiple comparisons test was performed on flow cytometry data. n = 3–4/group. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Error bars represent standard deviation.
www.oncotarget.com
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Ex vivo biodistribution demonstrated significant
clearance through liver by day 9 in MM.1S SQ and
IV mice. Due to their large size (~150 kDa), IgG
antibodies such as DARA are primarily catabolized via
the liver [31]. The greater hepatic uptake of DARADM1 relative to native DARA can be attributed to the
higher hydrophobicity associated with ADCs, resulting
in greater reticuloendothelial system clearance [32, 33].
These differences in liver uptake did not affect the tumor
targeting ability of DARA-DM1, as seen in the ex vivo
biodistribution as well as fluorescent microscopy and
flow cytometry studies on the excised tumor tissue, but
may have contributed to the differences in TBR at later
time points when compared to DARA in the MM.1S
SQ mice. It should be noted that DARA does not bind
to murine CD38, therefore, in combination with the
lack of a competent immune system, mice are not an
ideal species for evaluating the off-target toxicity of the
intact humanized ADCs. Future studies in humanized,
immunocompetent mouse models of MM that can
recapitulate the microenvironmental interactions with MM
tumors are warranted.
Our studies demonstrate that conjugation of DM1
to the native DARA significantly enhanced its therapeutic
efficacy in vitro and in vivo. Fluorophore labelling did not
affect the stability or activity of the biologic and showed
that both DARA-IR and DARA-DM1-IR had similar
binding and biodistribution profiles. These imaging
techniques can be applied to other immunotherapies
and antibody conjugates under investigation in animal
models of diverse hematologic cancers to evaluate similar
parameters demonstrated in this article. Future studies can
help in mechanistically understanding these therapies to
enhance response and overcome resistance in treatment
of these cancers.

did not demonstrate any cytotoxicity in either cell line,
likely due to the lack of effector cells for the antibody to
induce cell killing. Our flow cytometry and fluorescence
microscopy studies showed that these differences in
cytotoxicity may be due to differences in binding and
internalization of DARA-DM1 in the MM.1S and U266
cells. While DARA-DM1 bound to both cell lines, we
showed that there is significantly reduced binding and
lysosomal internalization intracellularly in U266 cells
than in MM.1S cells, corresponding with reduced CD38
expression and thus requiring greater concentration of
DARA-DM1 to induce cytotoxicity. This is consistent
with ADCs composed of non-cleavable linkers, which
require lysosomal proteolytic degradation of the antibody
[26]. These studies, additionally, corroborated that the
conjugation of IRDye800 at a DOL of ~1.3–1.4 did not
affect the stability or functional properties of DARA or
DARA-DM1.
DARA-DM1 demonstrated significant in vivo
single-dose efficacy within ~ 4 days in MM.1S IV mice
compared to the native DARA. While DARA-treated
mice showed reduced tumor burden 33 days post-tumor
inoculation, DARA-DM1-treated mice showed early
and near complete elimination of tumor burden with
no weight loss observed in either mouse cohort. DARA
monotherapy was likely efficacious in vivo due to ADCP
activity [27] with the presence of normal macrophage and
granulocyte populations in SCID beige mice [28]. These
results demonstrated that, while DARA monotherapy still
had significant therapeutic efficacy, conjugation of DM1
to DARA allowed for early and sustained elimination
of tumor burden. DARA-DM1-IR and DARA-IR were
imaged in MM.1S SQ and MM.1S IV mice to evaluate the
tissue biodistribution and tumor targeting of DARA-DM1
in relation to DARA. Our in vivo imaging results showed
that both immunoconjugates had high specificity to GFP+
tumor lesions in both mouse models. We, and others,
have previously demonstrated that IV injection of human
myeloma cells results in diffuse tumor growth in variable
regions of bone marrow in mice compared to the localized
tumor burden observed in MM.1S SQ mice [29, 30]. MM
is a plasma cell disorder that causes significant skeletal
morbidity within the bone marrow niche. As anticipated,
both DARA-DM1-IR and DARA-IR uptake was observed
in bone marrow regions in the MM.1S IV mice including
skull, long bones and spine. Spatial tumor heterogeneity
is characteristic of MM and the presence of circulating
tumor cells may be contributing to the uptake of MM cells
in different bone regions. Differences in the efficiency of
tail vein injections of MM.1S cells and mouse-to-mouse
variability in cytokines such as IL-6 may additionally
be why some mice develop more tumor burden in one
region than others. SCID beige mice also have several,
normal lymphocyte populations, which may contribute to
allogeneic tumor rejection from the host immune system,
leading to variability in tumor uptake [28].
www.oncotarget.com

MATERIALS AND METHODS
Maytansinoid and fluorophore conjugation of
DARA
Daratumumab (Darzalex, Janssen) was generously
donated by the Centre of Advanced Medicine pharmacy,
Washington University in St. Louis. DARA-DM1 was
synthesized through a one-step reaction. The noncleavable linker, SMCC, conjugated to DM1 (MedKoo
Biosciences) was conjugated to DARA via one-step
N-hydroxysuccinimide ester reaction at an antibody
concentration of 2.5 mg/mL in 1X PBS for 2 hours. A DAR
of 20 to 1 was used for conjugation. Unconjugated drug
was removed by desalting Zeba spin columns (Thermo
Fisher). The final DAR of DARA-DM1 was calculated to
be 3.2 via mass spectrometry. DARA, DARA-DM1 and
non-specific IgG (Sigma Aldrich) were then conjugated to
the NIR dye, IRDye800 (Li Cor Biosciences), according
to the manufacturer’s instructions. Briefly, antibodies
2046
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were reacted at an antibody concentration of 2.5 mg/
mL in 0.1M potassium phosphate buffer (pH 8.5) for 2
hours. Dye to antibody molar ratio of 3 to 1 was used.
Unconjugated dye was also removed by desalting Zeba
spin columns. The DOL was determined using the
DU-640B spectrophotometer (Beckman Coulter) to
measure fluorophore absorbance at 774 nm and antibody
absorbance at 280 nm, corrected for the fluorophore
(Supplementary Figure 1). The DOL is defined as the
average dye to protein concentration ratio.
Fluorescence emission was measured using
the Fluorolog-3 spectrofluorometer (Horiba). After
purification, conjugates were run on sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
(Bio-Rad) in the presence of 1X PBS and human serum
(Sigma Aldrich) at 37°C at incubation intervals of 1, 5
and 7 days. Gels were scanned using the Odyssey CLx
(Li Cor) measured at 800 nm channel, and images were
analyzed in Li Cor Image Studio version 5.2 software.

buffer (made with 1X PBS, 0.5M Ethylenediaminetetraacetic
acid disodium salt dihydrate (EDTA) (Corning) and 0.5%
Bovine Serum Albumin (Inveon)). Non-specific binding was
determined by incubating cells in the presence of excess (50fold) unlabelled DARA for 1 hour before incubating with
DARA-DM1-IR. Cells were immediately analyzed on the
LSR Fortessa (BD).
To evaluate the lysosomal uptake of the DARA
conjugates, MM.1S and U266 cells were incubated with
75 µg/mL of DARA-DM1-IR and DARA-IR, respectively,
for 3 hours. Cells were washed twice in 1X PBS and
fixed and permeabilized with CytoFAST Fix and Perm
buffer (BioLegend). Cells were then stained with PE antihuman CD107a (LAMP-1) antibody (BioLegend) in the
dark for 30 minutes. Cells were washed twice in FACS
buffer and immediately analyzed on the LSR Fortessa.
7-aminoactinomycin D (Thermo Fisher Scientific)
(7AAD)– population was considered as viable tumor
cells and used for statistical analysis for both studies. PE
mouse anti-human CD38 (BD) was used to evaluate CD38
expression on MM.1S and U266 cells. Blue laser (Ex. 488
nm) was used to detect 7AAD (Em. 695/40 nm), yellow
laser (Ex. 552 nm) was used to detect PE (Em. 585/15 nm)
while red laser (Ex. 640 nm) was used to detect IRDye800
(Em. 780/60 nm). Flow cytometry data was analyzed with
FlowJo Version 10.6.2 software.

Cell culture
The human myeloma MM.1S and U266 cells
were obtained from ATCC. MM.1S cells were modified
to express GFP and click beetle red luciferase (MM.1SGFP-luc) by the DiPersio laboratory (Professor John F.
DiPersio, Department of Medicine, Washington University
School of Medicine, St Louis, USA) in 2014. Cells were
tested negative for mycoplasma by the Washington
University Genome Engineering and induced Pluripotent
Stem Cell Core via MycoAlert PLUS Mycoplasma
Detection Kit (Lonza) in 2014 and 2018. All cell lines
were passaged 4–5 times following thaw before use in in
vitro and in vivo studies. Cells were cultured in Roswell
Park Memorial Institute (RPMI) 1640 medium (Thermo
Fisher Scientific) supplemented with 10% heat inactivated
fetal bovine serum (FBS) (Sigma Aldrich) and 1%
penicillin/streptomycin (Inveon) at 37°C in a humidified
environment with 5% CO2.

Live cell microscopy
300,000 MM.1S-GFP-luc cells/mL were seeded
into 6-well tissue culture-treated plates (Corning) and
incubated with 150 µg/mL of DARA-IR and DARADM1-IR at 37°C for 3 hours in 1X PBS. Cells were then
washed twice in 1X PBS and immediately imaged on Cell
Discoverer 7 (Zeiss) in the GFP (Ex./Em. 465 nm/520 nm)
and Cy5 (Ex./Em. 640 nm/680 nm) wavelength channels
with a 20X objective. Microscopy images were acquired
with Zeiss ZEN 3.2 (blue edition) software and exported
to and analyzed with NIH Image J software.

Cytotoxicity studies

Animal models

The in vitro activity of DARA conjugates was
tested using the CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega) on MM.1S and U266
cells plated at 2.5 × 104 cells per well in 96-well roundbottomed plates in triplicate and exposed to ADCs at
different concentrations (0–10 µg/mL) for 72 hours. IC50
values for ADCs were calculated with GraphPad Prism
Version 9.1.0 software.

All animal studies were performed in accordance
with the Institutional Animal and Use Committee of
Washington University School of Medicine. Mice were
anesthetized for all treatments and imaging with 2% v/v
isoflurane/100% O2. Female 1–3 month old fox chase
SCID mice (Charles Rivers Laboratories) were injected
with 3 × 106 MM.1S-GFP-luc cells in 100 µL 1X PBS SQ
or IV via lateral tail vein. Tumor burden was monitored
weekly via BLI prior to administration of DARA
conjugates in both mouse models. For imaging studies
in MM.1S SQ and IV mice, mice were randomized into
respective cohorts when a mean bioluminescence flux of
1 × 109 photons/second was achieved.

Cell uptake and internalization studies
MM.1S and U266 cells were incubated with 75 µg/mL
of DARA-DM1-IR in 1X PBS for 1 hour. Cells were then
washed twice in fluorescence activated cell sorting (FACS)
www.oncotarget.com
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were collected with Olympus Cells Standard 1.6 software
and exported into NIH ImageJ software for analysis.

Weekly BLI was performed on MM.1S IV mice
until they reached a mean bioluminescence flux of 6 × 106
photons/second. Mice were then randomized into untreated
and treated cohorts (n = 6–7/group). Treated mice were
provided DARA and DARA-DM1 intraperitoneally (i.p.)
at a single dose of 4 mg/kg of body weight in 1X PBS.
Additional BLI was performed twice per week to measure
tumor cell viability for 6–7 weeks.

Ex vivo flow cytometry
Viable cells were obtained from tibial and femoral
bone marrow flush from MM.1S IV mice, washed in
FACS buffer, stained and immediately analyzed with
LSR Fortessa. For GFP+ tumor graft viability, 7AAD–/
GFP+ population was considered as viable tumor cells
and lasers were used as previously described. Blue laser
(Ex. 488 nm) was used to detect FITC (Em. 530/30 nm).
Binding of DARA-IR and DARA-DM1-IR to MM cells in
the bone marrow was assessed using MFIs of IRDye800.
Flow cytometry data was analyzed with FlowJo Version
10.6.2 software as previously described.

In vivo and ex vivo fluorescence imaging studies
DARA-DM1-IR and DARA-IR, respectively, was
administered IV in 1X PBS at 4 mg/kg of body weight
in MM.1S SQ and MM.1S IV mice (n = 3–4/group). For
MM.1S SQ mice, daily optical imaging in the GFP (Ex./
Em. 480 nm/535 nm) and IRDye800 channels (Ex./Em.
785 nm/820 nm) was performed up to 9 days following
injection using the IVIS Spectrum CT (Perkin Elmer).
For MM.1S IV mice, optical imaging in the GFP (Ex./
Em. 480 nm/535 nm) and IRDye800 channels (Ex./Em.
785 nm/820 nm) was performed 9 days following injection
using the Optix MX3 time-domain diffuse optical
imaging system (Advanced Research Technologies).
Prior to imaging, hair was removed by gentle clipping and
depilatory cream to improve light transmission. Following
imaging, mice were sacrificed at appropriate time points
and tissue was excised. GFP (Ex./Em. 480 nm/535 nm)
and IRDye800 (Ex./Em. 780 nm/820 nm) fluorescent
images of excised tissue were acquired on the IVIS
Spectrum CT (Perkin Elmer), respectively. TBRs were
calculated from IRDye800 fluorescent images of MM.1S
SQ mice by drawing equivalently-sized ROIs in NIH
ImageJ software around GFP+ tumor-bearing regions and
non-fluorescent (background) regions on the contralateral
side of the mouse and measuring total radiant efficiency
(TRE). TMRs in ex vivo GFP and IRDye800 fluorescent
images were calculated in Perkin Elmer Living Image
4.7.1 software. Analysis of ex vivo fluorescent images
was performed by measuring TRE from ROIs drawn
around bone and muscle tissue. TMRs were calculated by
dividing TREs of tissue by TREs of muscle tissue of each
respective mouse.

Statistical analysis
All data is presented as mean ± standard deviation
and statistical analysis was performed using GraphPad
Prism Version 9.1.0 software. Statistical significance
between cohorts was calculated using Student t-test and
one-/two-way analysis of variance (ANOVA) followed
by Sidak’s multiple comparisons test, unless specified
otherwise. P values of less than 0.05 were considered
statistically significant.

Abbreviations
DARA: Daratumumab; ADC: Antibody-drug
conjugate; CD38: Cluster of Differentiation 38; SQ:
Subcutaneous; IV: intravenous; IR: IRDye800; GFP:
Green fluorescence protein.
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